OSSR Ossur hf.

Sprinters Using Össur Technology Dominate in Rio

Athletes using Össur carbon fiber blades were in the spotlight at the 2016 Paralympic Games in Rio, setting new World and Paralympic records and winning a record number of medals, the company announced today.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160926005473/en/

Athletes using Össur carbon fiber blades were in the spotlight at the 2016 Paralympic Games in Rio,  ...

Athletes using Össur carbon fiber blades were in the spotlight at the 2016 Paralympic Games in Rio, setting new World and Paralympic records and winning a record number of medals. In below-knee amputee sprinting, all medalists in the men’s 100m, 200m and 400m races wore the company’s iconic Cheetah running blades. (PHOTO COURTESY OF ÖSSUR)

Össur had a particularly strong showing in below-knee amputee sprinting, with all medalists in the men’s 100m, 200m and 400m races wearing the company’s iconic Cheetah running blades.

Highlights of Össur Athlete Performances

Members of Team Össur and Össur Ambassadors won a total of 12 Gold, 7 Silver and 7 Bronze Paralympic medals in Rio, including:

  • Double-Gold Medalist and Team Össur athlete Marie-Amelie Le Fur of France, who set two new World Records in the Long Jump and T44 400m Sprint
  • Double-Gold Medalist and Team Össur athlete Jody Cundy of Great Britain, who set a new World Record in Mixed C1-5 750m team sprinting in Cycling
  • Gold Medalist, reigning World Champion and Team Össur member Markus Rehm of Germany, who had a remarkable 8.21m in the men’s T44 Long Jump
  • Double-Medalist and Team Össur member Richard Whitehead of Great Britain, who successfully defended his 2012 Paralympic Gold Medal in the T42 200m Sprint, and also took Silver in the T42 100m Sprint
  • Silver Medalist swimmer and Team Össur member Rudy Garcia-Tolson, who set a new American Record in the 100m event, and took Silver in the 200m Individual Medley
  • Bronze Medalist and Össur Ambassador Mohamed Lahna, who competed in the Paralympics’ historic, first-ever Triathlon event

“We salute the exceptional performance of all Team Össur members and Ambassadors who competed at the Rio Paralympic Games. Their accomplishments elevated para-athletic sport to new heights, and have shown inarguably that our Cheetah technology remains the prosthesis of choice for world-class athletes,” said Jon Sigurdsson, Össur’s President and CEO. If its athletes were counted as a country, Sigurdsson added, Össur’s Gold Medal wins would have ranked it as 9th overall among all participating nations.

About Össur

Össur (NASDAQ: OSSR) is a global leader in non-invasive orthopaedics that help people live a life without limitations. Its business is focused on improving people’s mobility through the delivery of innovative technologies within the fields of Prosthetic, Osteoarthritis and Injury Solutions. A recognized “Technology Pioneer,” Össur invests significantly in research and product development—its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur’s educational programs and business solutions. Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com

EN
26/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ossur hf.

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Jesper Ingildsen
  • Jesper Ingildsen

Embla Medical (Buy, TP: DKK35.50) - Better start to the year than expe...

The c4% organic growth in Q1 was better than feared (consensus c3%), and with growth momentum likely to pick up in the coming quarters, we expect the company to reach c6% (previously c5%) in 2025. It kept its 2025 EBITDA margin guidance despite steep tariff exposure, citing high uncertainty and mitigation efforts. We reiterate our BUY with a raised target price of DKK35.5 (34).

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Jesper Ingildsen
  • Jesper Ingildsen

Embla Medical (Buy, TP: DKK34.00) - All eyes on tariffs

We expect a slower start to the year than previously, but a likely decent Q1 EBITDA margin, helped by last year’s cost cutting and product mix. We expect the focus to be on potential tariff effects, where we estimate a 10–15% hit on EPS mainly related to Bracing & Support (B&S) produced in China and sold to the US. We reiterate our BUY, but have reduced our target price to DKK34 (39).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch